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Herpes simplex viruses (HSV) are among the most widespread 
causative agents of human viral infections. HSV-2 is one of the 
commonest causes of genital disease, while HSV-1 is associated 
primarily with orolabial ulceration; however, recent changes in 
HSV epidemiology showed an increase in genital and neonatal 
herpes particularly caused by HSV-1. The main purpose of this 
study was to assess the seroprevalence of HSV-1 and HSV-2 in 
a random population in Siena (central Italy) in 2000, 2005 and 
2013-2014 and in Bari (southern Italy) in 2005. Moreover, a pre-
liminary study was conducted to investigate the spread of HSV 
infection in a population of pregnant women and infants in Bari 
in 2003, 2004 and 2005. Human serum samples were tested for 
the presence of specific anti-HSV-1 and anti-HSV-2 IgG antibod-
ies using a commercially available ELISA test. For the primary 
purpose, seroprevalence rates observed in Siena were compared 
over the years sampled and with the seroprevalence rate found in 
Bari. Results of seroprevalence in Siena show a decreased trend 
for both viruses, especially in adolescents and young adults; 
moreover, HSV-2 seroprevalence rates found in the two cities 
suggest geographical differences. For the secondary purpose, 
prevalence rates among pregnant women were compared with the 
seroprevalence found in women of the general population. No sig-
nificant difference in prevalence rates were found among pregnant 
women, while results indicate both viruses are a source of infec-
tion in infants.
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Summary
Introduction
Herpes simplex virus (HSV) is one of the most wide-
spread infections in humans, affecting 60-95% of the 
adult population worldwide. After entering the host, the 
virus establishes persistent and latent infection in neu-
ronal ganglia, from which it can reactivate periodically 
causing recurrent infections. Most infections are sub-
clinical; symptoms consist primarily of ulcerative lesions 
at the site of infection and, although rare, complications 
such as blindness, encephalitis and aseptic meningitis can 
occur, especially in immunocompromised hosts  [1,  2]. 
Moreover, the acquisition of HSV during pregnancy is 
associated with miscarriage, prematurity, and congenital 
and neonatal herpes. HSV can cause severe infections 
in newborn by vertical transmission in utero or, in most 
cases, during vaginal delivery through contact with HSV-
infected genital tract secretions, with a high mortality and 
neurodevelopmental disability [3-5].
There are two types of HSV, HSV-1 and HSV-2, both 
transmitted by direct contact with infected secretions. 
HSV-2 is transmitted sexually, resulting in one of the 
most common genital diseases, affecting adolescents and 
adults and facilitating HIV transmission  [6, 7]. HSV-1 
infection is associated predominantly with orolabial ul-
ceration and occurs mostly by nonsexual contacts during 
childhood after the disappearance of maternal antibodies 
in the first year of life [7, 8]. However, recent changes 
in herpes infection epidemiology reported an increase in 
genital and neonatal herpes due to HSV-1 [9].
Nevertheless, many infections remain asymptomatic or 
do not require health care intervention, resulting in an 
underestimation of the spread of HSV. Serological tests 
based on the use of type-specific immunoassays that dis-
tinguish antibodies to HSV-1 and HSV-2, can recognize 
both symptomatic and asymptomatic infections, facili-
tating a better understanding of HSV epidemiology [6].
In Italy, some studies have investigated the seroprevalence 
of these viruses in different populations considered to be 
at low or high risk of acquiring the infection. According to 
these studies, HSV-1 infection is widespread, with sero-
prevalence rates of 93% in the adult population [10]. Con-
versely, the circulation of HSV-2 is more limited (5.5% 
in adults, according to Suligoi et al. [11]) and frequent-
ly associated with other sexually transmitted diseases 
(STD) [12-14]. Moreover, a HSV-2 seroprevalence study 
conducted on samples collected in 1998 showed 7.6% 
positivity to HSV-2 antibodies among pregnant wom-
en [11], comparable to 8.4% seroprevalence in a similar 
survey conducted in Northern Italy [15].
HSV infection control is of relevance for public health es-
pecially for mitigating the risk of neonatal herpes and as-
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sociated diseases; thus, monitoring the epidemiology 
of HSV infections is an important tool for prevention 
and control strategies, as suggested by Woestenberg 
et  al.  [16]. In Italy, a characterization of HSV infec-
tions in the general population over time is lacking. 
To revise the epidemiology of HSV in Italy, a seroepi-
demiological study was carried out to determine the 
HSV-1 and HSV-2 antibody prevalence in the general 
population of two cities from different geographical 
areas (Siena, central Italy and Bari, southern Italy), 
making a comparison between seroprevalence rates 
obtained over a period of nearly 15 years. Moreover, 
a preliminary study was carried out in a small popu-
lation of samples of pregnant women and infants, to 
evaluate HSV as a source of infection in infants.
Materials and methods
HSV antibody tests were performed on human serum 
samples from the internal serum bank of the Laboratory 
of Molecular Epidemiology, Department of Molecular 
and Developmental Medicine, University of Siena. The 
samples had been anonymously collected in compliance 
with Italian law on Ethics; the only information avail-
able for these subjects were age, gender and state of 
pregnancy.
1,776 samples (640 in 2000, 636 in 2005 and 500 in 
2013-2014) collected in the Siena area and 168 sam-
ples collected in 2005 in the province of Bari were 
tested for the presence of specific anti-HSV-1 and anti-
HSV-2 IgG antibodies. In addition, 91 samples from 
pregnant women and 70 samples from infants collect-
ed in the province of Bari in 2003, 2004 and 2005, 
were tested. In particular, infants were subdivided in 
two age-groups, 0-11 months of age and 1 year of age, 
considering the waning of maternal antibodies over a 
period of 6-12 months [17]. A population summary is 
shown in Table Ia, Ib and Ic.
Type specific serum antibodies to HSV-1 and HSV-2 
were detected by commercial ELISA kits BEIA HSV 
1 IgG and BEIA HSV 2 Rec IgG (TechnoGenetics, 
Milano, Italy). ELISA assays were performed in accord-
ance with the manufacturer’s instructions. According to 
the manufacturer, the tests have sensitivity and specific-
ity of 98.7% and 100% for HSV-1 and 94.1% and 98.5% 
for HSV-2 respectively. Cut-off levels were > 1.1 for se-
ropositivity and < 0.9 for seronegativity; samples with 
borderline results (between 0.9 and 1.1) were excluded 
from the study.
Sex and age-specific seroprevalence rates were calcu-
lated, along with the corresponding 95% CI. Statisti-
cal analysis was performed using the Yates corrected 
chi-squared test to compare prevalence rates among 
different groups and the chi-squared test for the trend 
to evaluate possible tendencies in seroprevalence rates 
over time. Statistical significance was set at p < 0.05, 
two tailed.
Results
A total of 2105 serum samples were tested by ELISA as-
say, 45 of which yielded borderline results and were ex-
cluded from the statistical analysis. Samples collected in 
the general population of Siena and Bari were divided by 
sex and classified into eight age groups: 0-14 (children), 
15-19 (adolescents), 20-24 (young adults), 25-29, 30-34, 
35-39, 40-49 and > 50 years old. Samples collected from 
pregnant women were divided in four age groups: 20-24, 
25-29, 30-34 and 35-39 years old, while samples from 
infants were divided into 0-11 months and 1-year-old.
HSV-1 seroprevalence in the general 
population
The results for specific IgG antibodies against HSV-1 in 
samples collected in Siena are reported in Table II.
Overall, HSV-1 seroprevalence declined significantly 
(p < 0.001) from 2000 to 2013-2014 in the study popu-
lation, in particular rates by sex showed a decrease of 
14.5% in women and 22% in men; however, the prev-
alence remained significantly higher among women 
(p = 0.003).
In all the years considered in this study, a steady in-
crease in the proportion of HSV-1 seropositive occurred 
Tab. I. General population of Siena in 2000, 2005 and 2013-2014 (a), 
general population of Bari 2005 and pregnant women of Bari 2003, 
2004 and 2005 (b) and infants of Bari 2003, 2004, 2005 (c).
a)
Age 
groups
Siena 2000 Siena 2005 
Siena  
2013-2014 
M F TOT M F TOT M F TOT
0-14 60 40 100 39 19 58 10 5 15
15-19 8 41 49 10 10 20 9 13 22
20-24 12 39 51 10 11 21 23 22 45
25-29 12 42 54 7 29 36 26 23 49
30-34 16 50 66 11 28 39 19 31 50
35-39 20 31 51 16 37 53 25 36 61
40-49 43 63 106 39 59 98 51 59 110
50+ 54 90 144 149 141 290 74 71 145
Total 225 396 621 281 334 615 237 260 497
b)
Age groups Bari 2005 Bari 2003-2004-2005
M F TOT Pregnant
0-14 28 28 56 -
15-19 10 6 16 -
20-24 5 7 12 9
25-29 6 15 21 30
30-34 7 25 32 34
35-39 13 18 31 18
Total 69 99 168 91
c)
Age groups Bari 2003-2004-2005
0-11 months 34
1 year old 34
Total 68
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with age (p < 0.001). As shown in Figure 1, from 2000 
to 2013-2014 seroprevalence declined significantly 
(p < 0.001) among adolescents and young adults (from 
87.8% and 96.1% in 2000 to 27.3% and 35.6% in 2013-
2014 respectively) as well as for 35-39- and 40-49-years-
old groups; moreover, there is an important decrease 
among 30-34 years old (p = 0.018) and in subjects over 
50 (p = 0.003). Among children and 25-29 years old sub-
jects, there were no significant changes.
The greatest increase in infections in 2000 was amongst 
adolescents (p = 0.006 with children), whilst in 2013-
2014 it was in the 25-29 years group (73.5%; p < 0.001 
with 20-24 age group of the same year). In particular, 
a significant difference was found between 20-24 and 
25-29 year old men (p  =  0.015), but also in women 
(p = 0.024).
The seroprevalence in samples collected in Siena in 
2005 was compared with the results of the samples col-
lected in Bari in the same year (Tab. III). No significant 
differences were found between the two cities.
HSV-2 seroprevalence in the general 
population
The results for specific IgG antibodies against HSV-2 in 
the samples collected in Siena are reported in Table IV.
Tab. II. HSV-1 seroprevalence in population of Siena in 2000, 2005 and 2013-2014, divided by sex (male, M and female, F) and age groups.
Age 
groups
Siena 2000 (%) Siena 2005 (%) Siena 2013-2014 (%)
M F TOT M F TOT M F TOT
0-14
42/60 
(70)
23/40 
(57.5)
65/100 
(65)
21/39 
(53.8)
9/19 
(47.4)
30/58 
(51.7)
3/10 
(30)
3/5 
(60)
6/15 
(40)
15-19
8/8 
(100)
35/41 
(85.4)
43/49 
(87.8)
6/10 
(60)
1/10 
(10)
7/20 
(35)
2/9 
(22.2)
4/13 
(30.8)
6/22 
(27.3)
20-24
10/12 
(83.3)
39/39 
(100)
49/51 
(96.1)
6/10 
(60)
8/11
(72.7)
14/21 
(66.7)
7/23 
(30.4)
9/22 
(40.9)
16/45 
(35.6)
25-29
11/12 
(91.7)
38/42 
(90.5)
49/54 
(90.7)
5/7 
(71.4)
25/29 
(86.2)
30/36 
(83.3)
18/26 
(69.2)
18/23 
(78.3)
36/49 
(73.5)
30-34
14/16 
(87.5)
47/50 (
94)
61/66 
(92.4)
9/11 
(81.8)
27/28 
(96.4)
36/39 
(92.3)
10/19 
(52.6)
28/31 
(90.3)
38/50 
(76)
35-39
20/20 
(100)
29/31 
(93.5)
49/51 
(96.1)
15/16 
(93.7)
29/37 
(78.4)
44/53 
(83)
14/25 
(56)
27/36
(75)
41/61 
(67.2)
40-49
38/43
(88.4)
62/63 
(98.4)
100/106 
(94.3)
31/39 
(79.5)
54/59 
(91.5)
85/98 
(86.7)
36/51
(70.6)
47/59
(79.7)
83/110 
(75.4)
50+
47/54 
(87)
89/90 
(98.9)
136/144 
(94.4)
138/149 
(92.6)
131/141 
(92.9)
269/290 
(92.8)
58/74
 (78.4)
64/71 
(90.1)
122/145 
(84.1)
Total
190/225 
(84.4)
362/396 
(91.4)
552/621 
(88.9)
231/281 
(82.2)
284/334 
(85)
515/615 
(83.7)
148/237 
(62.4)
200/260 
(76.9)
348/497 
(70)
Fig. 1. HSV-1 seroprevalence in population of Siena in 2000, 2005 and 2013-2014, divided by age groups with 95%CI.
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HSV-2 seroprevalence was halved between 2000 
and 2013-2014 (from 22.4% to 11.5%, p  <  0.001). In 
2000 the prevalence among males and females exhib-
ited no difference; in almost 15 years, both decreased 
(p < 0.001), but in 2013-2014 the prevalence was higher 
among males than females, even if this difference is not 
considered to be statistically significant.
In almost all age groups, seroprevalence decreased in the 
time span considered. The greatest decreases were ob-
served particularly in adolescents (p = 0.005) and young 
adults (p < 0.001); a decrease was observed also in chil-
dren from a value of 8% in 2000 to 0% in 2013-2014, but 
the difference was considered to be not statistically sig-
nificant. In contrast, in 35-39 and 40-49 year old subjects 
no significant differences over the years were observed.
Considering the period 2013-2014, HSV-2 seroposi-
tivity is distributed only among the general population 
over 20 years of age, but over the years it was possible 
to observe some differences in seroprevalence patterns 
(Fig.  2). While in 2000 30.6% of adolescents showed 
HSV-2 positivity and the peak of infection was achieved 
in 20-24 year old subjects (47.1%) with a decrease up 
to 13.7% in 35-39-year old group, in 2013-2014 none 
of the adolescents in the study showed positivity to the 
virus. In the same years, the 20-24 year old age group 
remains the most affected in conjunction with that of 25-
29 year olds; also there is a second increase in seropreva-
lence in people over 35 years.
The seroprevalence in samples collected in Siena in 
2005 was compared with the results of samples collected 
in Bari in the same year (Tab. V).
The seroprevalence observed in the two cities showed a 
significant difference in the general population (13.2% 
Tab. IV. HSV-2 seroprevalence in population of Siena in 2000, 2005 and 2013-2014, divided by sex and age groups.
Age 
groups
Siena 2000 (%) Siena 2005 (%) Siena 2013-2014 (%)
M F TOT M F TOT M F TOT
0-14
5/60 
(8.3)
3/40 
(7.5)
8/100
(8)
1/39 
(2.6)
1/19 
(5.3)
2/58 
(3.4)
0/10 
(-)
0/5 
(-)
0/15 
(-)
15-19
1/8 
(12.5)
14/41 
(34.1)
15/49 
(30.6)
1/10 
(10)
1/10 
(10)
2/20 
(10)
0/9 
(-)
0/13 
(-)
0/22
(-)
20-24
7/12 
(58.3)
17/39 
(43.6)
24/51 
(47.1)
1/10
(10)
1/11 
(9.1)
2/21 
(9.5)
3/23
(13)
2/22 
(9.1)
5/45 
(11.1)
25-29
3/12 
(25)
16/42 
(38.1)
19/54 
(35.2)
1/7
(14.3)
7/29 
(24.1)
8/36 
(22.2)
4/26 
(15.4)
1/23 
(4.3)
5/49 
(10.2)
30-34
6/16 
(37.5)
8/50 
(16)
14/66 
(21.2)
3/11 
(27.3)
4/28 
(14.3)
7/39 
(17.9)
1/19
(5.3)
0/31 
(-)
1/50 
(2)
35-39
7/20 
(35)
0/31
(-)
7/51 
(13.7)
2/16 
(12.5)
7/37 
(18.9)
9/53 
(17)
5/25 
(20)
3/36 
(8.3)
8/61 
(13.1)
40-49
4/43 
(9.3)
13/63 
(20.6)
17/106 
(16)
1/39 
(2.6)
14/59 
(23.7)
15/98 
(15.3)
9/51 
(17.6)
9/59 
(15.2)
18/110 
(16.4)
50+
16/54 
(29.6)
19/90 
(21.1)
35/144 
(24.3)
15/149 
(10.1)
20/141 
(14.2)
35/290 
(12.1)
11/74 
(14.9)
9/71 
(12.7)
20/145 
(13.8)
Total
49/225 
(21.8)
90/396 
(22.7)
139/621 
(22.4)
25/281
(8.9)
55/334 
(16.5)
80/615 
(13)
33/237 
(13.9)
24/260 
(9.2)
57/497 
(11.5)
Tab. V. HSV-2 seroprevalence in Siena and in Bari in 2005, divided by 
sex and age groups.
Age 
groups
Siena 2005 (%) Bari 2005 (%)
M F TOT M F TOT
0-14
1/39
(2.6)
1/19
(5.3)
2/58
(3.4)
1/28
(3.6)
1/28
(3.6)
2/56
(3.6)
15-19
1/10
(10)
1/10
(10)
2/20
(10)
0/10
(-)
0/6
(-)
0/16
()
20-24
1/10
(10)
1/11
(9.1)
2/21
(9.5)
1/5
(20)
0/7
(-)
1/12
(8.3)
25-29
1/7
(14.3)
7/29
(24.1)
8/36
(22.2)
0/6
(-)
2/15
(13.3)
2/21
(9.5)
30-34
3/11
(27.3)
4/28
(14.3)
7/39
(17.9)
0/7
(-)
2/25
(8)
2/32
(6.2)
35-39
2/16
(12.5)
7/37
(18.9)
9/53
(17)
1/13
(7.7)
0/18
(-)
1/31
(3.2)
Total
9/93
(9.7)
21/134
(15.7)
30/227
(13.2)
3/69
(4.3)
5/99
(5)
8/168
(4.8)
Tab. III. HSV-1 seroprevalence in Siena and in Bari in 2005, divided by 
sex and age groups.
Age 
groups
Siena 2005 (%) Bari 2005 (%)
M F TOT M F TOT
0-14
21/39
(53.8)
9/19
(47.4)
30/58
(51.7)
18/28
(64.3)
13/28
(46.4)
31/56
(55.4)
15-19
6/10
(60)
1/10
(10)
7/20
(35)
5/10
(50)
4/6
(66.7)
9/16
(56.2)
20-24
6/10
(60)
8/11
(72.7)
14/21
(66.7)
4/5
(80)
5/7
(71.4)
9/12
(75)
25-29
5/7
(71.4)
25/29
(86.2)
30/36
(83.3)
3/6
(50)
13/15
(86.7)
16/21
(76.2)
30-34
9/11
(81.8)
27/28
(96.4)
36/39
(92.3)
6/7
(85.7)
22/25
(88)
28/32
(87.5)
35-39
15/16
(93.7)
29/37
(78.4)
44/53
(83)
12/13
(92.3)
16/18
(88.9)
28/31
(90.3)
Total
62/93
(66.7)
99/134
(73.9)
161/227
(70.9)
48/69
(69.6)
73/99
(73.7)
121/168
(72)
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in Siena vs 4.8% in Bari, p  =  0.008), in particular in 
women (p = 0.02).
HSV-1 and HSV-2 seroprevalence among 
pregnant and infants
The prevalence of IgG antibodies against HSV-1 and 
HSV-2 in samples collected from pregnant women in 
Bari in 2003, 2004 and 2005 is shown in Table VI.
Among pregnant women, 91.2% and 9.9% showed an-
tibodies against HSV-1 and HSV-2 respectively, while 
8.8% were negative for both viruses. As shown in Table 
V, no significant differences were observed comparing 
pregnant and women of the same age of the general pop-
ulation collected in Bari 2005. In both populations, all 
subjects positive for anti HSV-2 IgG were also positive 
for anti HSV-1 IgG.++
Among infants, 38.2% and 30.9% showed anti-HSV-1 and 
anti-HSV-2 antibodies respectively (Tab.  VII). 16.2% of 
them had antibodies directed against both viruses, in par-
ticular 23.5% of the infants 0-11 months of age and 8.8% 
of infants 1-year-old. HSV-1 seroprevalence showed a sig-
nificant difference (p = 0.024) between infants 0-11 months 
of age and infants 1-year-old, while no difference was ob-
served for HSV-2, or for co-detection of both viruses.
Discussion
HSV-1 and HSV-2 are among the most widespread hu-
man viral infections. HSV-2 is one of the most common 
causes of genital disease, while HSV-1 is associated pri-
marily with orolabial ulceration; however, recently an 
increase in genital and neonatal herpes caused by HSV-1 
has been reported [7-9]. In Italy, the seroepidemiology 
of HSV infection has been investigated in populations 
associated with some risk factors, such as HIV infec-
tion  [13] or other STDs  [12, 14, 18], or considering a 
single serotype [10, 11].
The serological study presented here was conducted in 
order to estimate the seroprevalence of HSV-1 and HSV-
2 in a general population from Siena, analyzing potential 
differences in the spread of infection from 2000 to 2014 
and making a comparison with the seroprevalence in a 
general population from Bari. Moreover, a preliminary 
study was carried out in a small population of samples of 
pregnant women and infants, to investigate the spread of 
HSV as infection source of infection in infants.
As expected, analysis of data obtained from this study 
confirms the widespread prevalence of HSV-1 in the 
general population with seroprevalence rates higher than 
those to HSV-2.
The seroprevalence of HSV-1 declined significantly in 
the general population of Siena from 88.9% in 2000 to 
Fig. 2. HSV-2 seroprevalence in population of Siena in 2000, 2005 and 2013-2014, divided by age groups with 95% CI.
Tab. VI. HSV-1 and HSV-2 seroprevalence in Bari in 2003, 2004 and 
2005 in pregnant women and not pregnant women, divided by age 
groups..
Age groups Pregnant No pregnant
HSV-1
(%)
HSV-2
(%)
HSV-1
(%)
HSV-2
(%)
20-24
8/9
(88.9)
2/9
(22.2)
5/7
(71.4)
0/7
(-)
25-29
27/30
(90)
5/30
(16.7)
13/15
(86.7)
2/15
(13.3)
30-34
32/34
(94.1)
1/34
(2.9)
22/25
(88)
2/25
(8)
35-39
16/18
(88.9)
1/18
(5.6)
16/18
(88.9)
0/18
(-)
Total
83/91
(91.2)
9/91
(9.9)
56/65
(86.1)
4/65
(6.1)
Tab. VII. HSV-1 and HSV-2 seroprevalence in Bari in 2003, 2004 and 
2005 among infants 0-11 months and 1-year-old.
Age groups HSV-1 (%) HSV-2 (%)
0-11 months 18/34 (52.9) 11/34 (32.3)
1 year old 8/34 (23.5) 10/34 (29.4)
Total 26/68 (38.2) 21/68 (30.9)
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70% in 2013-2014. This decrease has also been observed 
in other industrialized countries [6, 7, 16, 19] and associ-
ated with changes in socioeconomic status and family 
size, with improvements in living and hygiene condi-
tions, as suggested by the same studies. The strongest 
decrease is observed in adolescents and young adults; in 
2000 the peak of infection was achieved among adoles-
cents, while in 2013-2014 HSV-1 infection was mainly 
acquired in 25-29 year-old subjects. Lack of HSV-1 im-
munity at the start of sexual activity makes young peo-
ple more susceptible to genitally acquired HSV-1 infec-
tion [6, 19, 20]; women in particular are more suscepti-
ble to acquiring HSV-1, as well as HSV-2, as a genital 
infection because of a more vulnerable mucosal lining 
of the external genitalia  [21]. In this study it was not 
possible to distinguish orolabial infections from genital 
infections. However, considering the 2013-2014 popula-
tion, in every age group women show a higher rate of 
positivity than males of the same age, especially in the 
30-34-year-old group.
HSV-2 prevalence declined significantly from 22.4% in 
2000 to 11.5% in 2013-2014 among the general popu-
lation and, as with HSV-1, the strongest decrease is 
observed in adolescents and young adults. In samples 
collected in 2000, 30.6% of adolescents exhibited posi-
tivity to HSV-2 antibodies, and the peak of infection was 
reached among young adults, while in 2013-2014 sub-
jects who showed positivity to HSV-2 antibodies were 
over 20 years old. These results may reflect changes in 
sexual behavior, as acquisition of HSV-2 is considered 
a marker of previous sexual activity  [6]. A second in-
crease in HSV-2 seroprevalence was observed in people 
over 35 years of age without significant differences over 
the years, potentially correlated to a cumulative “sexual 
exposure” in older age groups. Considering the 2013-
2014 population, women have a lower seroprevalence 
value than men, even if the difference is not statistically 
significant. This figure is in contrast with what has been 
observed by Pebody et al. [6], which states that women 
generally have a higher seroprevalence than men. A pos-
sible explanation could be that prior HSV-1 infection 
may protect against HSV-2 by conferring cross-immu-
nity [7, 8, 22], even if it is still not known if a previous 
HSV-1 oral infection could confer the same protection as 
a HSV-1 genital infection.
While no differences were found among the general 
population of Siena and Bari for HSV-1 seroprevalence, 
HSV-2 antibody prevalence in Siena was higher than in 
Bari, especially in women, and additionally higher than 
those reported in Rome by Suligoi et al. [11]. These geo-
graphic differences could reflect historical differences in 
sexual behavior, as suggested by Pebody et al. [6], or dif-
ferences in prevention and control programmes designed 
into these population.
Among pregnant women 91.2% and 9.9% showed 
antibodies against HSV-1 and HSV-2 respectively. 
HSV-2 seroprevalence in this study is consistent with 
those observed in Rome (7.6%) and Northern Italy 
(8.4%) [11, 15], but nevertheless it is lower than that re-
ported among pregnant women in other countries, such 
as Germany (18%) and Finland (15.7%). Conversely, 
HSV-1 seroprevalence was higher (82% in Germany and 
70% in Finland) [7, 23]. 8.8% of the pregnant women in 
this study are negative to both viruses and therefore are 
at greater risk to acquire the infection during pregnancy 
and transmit it to a newborn [5, 24], considering that ap-
proximately 3% of women in Italy acquires HSV infec-
tion during pregnancy [25].
These data are confirmed by seroprevalence rates found 
in infants: 52.9% and 32.3% of children of 0-11 months 
of age show antibodies against HSV-1 and HSV-2 re-
spectively, resulting from an infection or inherited pas-
sively from the mother. After the first year of life HSV-1 
seroprevalence declines to 23.5%, while 29.4% of in-
fants show antibodies against HSV-2. Because maternal 
antibodies wane within the first year of life  [17], the 
presence of anti HSV-1 or HSV-2 antibodies in children 
1-year-old is indicative of infection. Comparing sero-
prevalence rates among infants 0-11 months and infants 
1-year-old it could be postulated that the presence of an-
ti-HSV-1 antibodies in the first months of life could be 
associated with infection or passively acquired maternal 
immunity, whilst antibodies directed against HSV-2 are 
almost always associated with HSV-2 infection, which 
is vertically transmitted more frequently than HSV-1 as 
suggested by other studies [5, 6].
The main importance of this study is that the detection of 
specific antibodies against HSV-1 and HSV-2 was con-
ducted on samples that had been randomly collected in a 
general population, allowing characterization of the spread 
of the infections not only in high-risk subgroups (e.g. STD 
clinic attendees). On the other hand, some age groups are 
numerically limited because of the method of the sample 
collection and the lack of information (e.g. marital status, 
living area, education level, employment, sexual activity 
and number of partners, symptoms or previous diagnosis 
of genital herpes) on the subjects involved did not allow an 
evaluation of the influence of factors that may be related to 
an increased risk of HSV infection. Unfortunately, no data 
about the circulation of HSV-1 and HSV-2 in the years be-
tween those studied were available, therefore it was not 
possible to assess any changes in trends or possible epi-
demic outbreaks in the population studied.
Conclusions
In conclusion, this study highlights a decreased trend in 
seropositivity for both HSV viruses, especially in ado-
lescents and young adults, updating data from previous 
studies and providing important information about the 
changing epidemiology of these infections in Italy as 
already observed in other countries. Moreover, preva-
lence rates found among pregnant women and infants 
indicate both viruses as a source of infection in infants, 
emphasizing the importance of prevention with vaccine 
development and adequate communication to healthcare 
workers and public.
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